Manish Sharma MD

Oncology•Grand Rapids, MI

Hematologic Oncology, Clinical Pharmacology

Co-Director of Clinical Research, START Midwest

Join to View Full Profile

5800 Foremost Dr SEGrand Rapids, MI 49546
Phone+1 616-954-5554

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2008 - 2011
University of California (San Francisco)Residency, Internal Medicine, 2004 - 2008
University of Michigan Medical SchoolClass of 2004

Certifications & Licensure

CA State Medical License 2006 - Present
MI State Medical License 2018 - 2025
IL State Medical License 2009 - 2020
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients Start of enrollment: 2009 Dec 12
Completed
Phase 1
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies Start of enrollment: 2012 Aug 29
Terminated
Phase 1
Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery Start of enrollment: 2012 Jun 13
Completed
Phase 1
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Start of enrollment: 2013 Sep 20
ACTIVE_NOT_RECRUITING
PHASE2
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy Start of enrollment: 2013 Jul 08
Active, not recruiting
Phase 2
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 1
A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors Start of enrollment: 2014 Apr 01
Completed
Phase 1
Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2014 Aug 25
Completed
Phase 2
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer Start of enrollment: 2015 Jun 01
Withdrawn
Phase 1
MGC018 With or Without MGA012 in Advanced Solid Tumors Start of enrollment: 2018 Nov 21
Terminated
Phase 1, Phase 2
Study of CPI-200 in Patients With Advanced Tumors Start of enrollment: 2019 Jul 01
Completed
Phase 1
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors Start of enrollment: 2020 Jan 23
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors.
Russell J Schilder, Drew Rasco, Manish R Sharma
Neoplasia. 2025-03-01
1 citations
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Maxime Chénard-Poirier, Aaron R Hansen, Martin E Gutierrez, Drew Rasco, Yan Xing
Investigational New Drugs. 2024-06-01
10 citations
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Nikhil I Khushalani, Patrick A Ott, Robert L Ferris, Tina Cascone, Dirk Schadendorf
Journal for Immunotherapy of Cancer. 2024-03-07

Lectures

Impact and influence of PET on imaging related endpoints in patients with Lymphoma using IWG-NHL or Lugano classification.
2019 ASCO Annual Meeting - 6/1/2019